A Novel Radiogenomics Biomarker for Predicting Treatment Response to PD-1 or PD-L1 Inhibition Immunotherapy in Patients With NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Thoracic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC
J Thorac Oncol 2023 Feb 09;[EPub Ahead of Print], M Chen, H Lu, SJ Copley, Y Han, A Logan, P Viola, A Cortellini, DJ Pinato, D Power, EO AboagyeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.